Study Group: Class Action Experts: Lawyers (US)(?)

The Lafferty study indicates that forced reductions of bankcard interchange fees in Australia have not significantly harmed issuer or network profits.  This is the exact opposite of what industry representatives had predicted.  If Lafferty is on target, interchange pricing...

The financial responsibity will lie with Baxter, not the FDA.  Perhaps moral or political responsibility (and fall out) will rest with the FDA, but that is of no help to those harmed by the Heparin.  Their only recourse is to sue the manufacturer.

Under the current administration, the FDA has tried to use drug approval as a shield.  In some cases, the current court has held warning approval to bar lawsuits.  However, this can be remedied by Congress explicitly clarifying that the FDA approval of a drug does not preempt state law....

Investors, including bankcard issuers, want the Visa IPO to be at least as successful as MasterCard's in '06. Visa's global legal problems, which are especially acute in the US and EU, could burden Visa far into the future. The US credit crunch could hold surprises for Visa, more so if Democrats...

To prevent the mortgage meltdown from spreading to payment cards, Congress will suspend aggressive reforms against bankcard lenders and other government pressure (from the feds and perhaps the DoJ) will help to minimize their risks in the interchange antitrust lawsuits.  Thus what Paulson...